You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

Advanced Lymphoma

Showing 1 - 25 of >10,000
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

nk/T-cell Lymphoma, Newly Diagnosed, Advanced Lymphoma Trial in Beijing (XPO1 inhibitor)

Recruiting
  • nk/T-cell Lymphoma
  • +2 more
  • XPO1 inhibitor
  • Beijing, Haidian, China
    ChinaPLAGH
Apr 18, 2023

Lymphoma, T-Cell, Cutaneous, Hodgkin Disease, Lymphoma, T-Cell, Peripheral Trial (SGN-35T)

Not yet recruiting
  • Lymphoma, T-Cell, Cutaneous
  • +5 more
  • (no location specified)
Nov 2, 2023

Hodgkin Lymphoma Trial in Cologne (Pembrolizumab)

Not yet recruiting
  • Hodgkin Lymphoma
  • Cologne, Germany
    1st Department of Medicine, Cologne University Hospital
Sep 19, 2023

Classic Hodgkin Lymphoma Trial (Concurrent penpulimab and AVD, Sequential penpulimab and AVD)

Not yet recruiting
  • Classic Hodgkin Lymphoma
  • Concurrent penpulimab and AVD
  • Sequential penpulimab and AVD
  • (no location specified)
Jul 10, 2023

Advanced Lymphoma, Advanced Malignant Solid Tumor, Advanced Pancreatic Carcinoma Trial in New Haven (BET Bromodomain Inhibitor

Recruiting
  • Advanced Lymphoma
  • +13 more
  • BET Bromodomain Inhibitor ZEN-3694
  • +2 more
  • New Haven, Connecticut
    Yale University Cancer Center LAO
Jun 29, 2022

Non-Hodgkin's Lymphoma, Relapsed, Non-Hodgkin's Lymphoma Refractory, Advanced Solid Tumor Trial (TR115)

Not yet recruiting
  • Non-Hodgkin's Lymphoma, Relapsed
  • +2 more
  • (no location specified)
Dec 6, 2022

Advanced or Metastatic Solid Tumors, Non-Hodgkin Lymphoma Trial in San Antonio (WTX-330)

Recruiting
  • Advanced or Metastatic Solid Tumors
  • Non-Hodgkin Lymphoma
  • San Antonio, Texas
    NEXT Oncology
Jan 6, 2023

Advanced Solid Tumor, Advanced Lymphoma Trial in United States (SNX281, Pembrolizumab)

Recruiting
  • Advanced Solid Tumor
  • Advanced Lymphoma
  • Denver, Colorado
  • +3 more
Apr 1, 2022

Advanced Solid Tumors, Relapsed/Refractory Non-Hodgkin Lymphoma, Relapsed/Refractory Multiple Myeloma Trial in Gyeonggi-do,

Recruiting
  • Advanced Solid Tumors
  • +2 more
  • GIC-102 (Allogeneic NK cells)
  • Gyeonggi-do, Korea, Republic of
  • +3 more
May 18, 2023

Advanced Solid Tumor, Refractory Non-Hodgkin Lymphoma Trial (HCB101)

Not yet recruiting
  • Advanced Solid Tumor
  • Refractory Non-Hodgkin Lymphoma
  • (no location specified)
May 28, 2023

Advanced Solid Tumors, B-cell Non-Hodgkin Lymphomas Trial (ATG-031)

Not yet recruiting
  • Advanced Solid Tumors
  • B-cell Non-Hodgkin Lymphomas
  • (no location specified)
Aug 31, 2023

B-cell Non-Hodgkin Lymphoma, Diffuse Large B Cell Lymphoma, Follicular Lymphoma Trial (IKS03)

Not yet recruiting
  • B-cell Non-Hodgkin Lymphoma
  • +4 more
  • (no location specified)
Dec 7, 2022

Advanced DLBCL, Extra-nodal Involvement, Large Mass, Radiotherapy Trial (6-8 cycles (21 days per cycle) of Standard R-CHOP

Not yet recruiting
  • Advanced Diffuse Large B-Cell Lymphoma
  • +2 more
  • 6-8 cycles (21 days per cycle) of Standard R-CHOP chemotherapy
  • Radiotherapy beyond standard R-CHOP Chemotherapy
  • (no location specified)
May 24, 2023

NK-T-Cell Lymphoma, Extranodal Trial (Pegaspargase Combined With Gemcitabine, Etoposide, Liposomal Mitoxantrone Hydrochloride

Not yet recruiting
  • NK-T-Cell Lymphoma, Extranodal
  • Pegaspargase Combined With Gemcitabine, Etoposide, Liposomal Mitoxantrone Hydrochloride and Dexamethasone (P-GEMD) regimen
  • (no location specified)
Mar 7, 2023

Advanced Cancer, Follicular Lymphoma, Peripheral T Cell Lymphoma Trial (BR1733)

Not yet recruiting
  • Advanced Cancer
  • +3 more
  • (no location specified)
Feb 27, 2023

Advanced Lymphoma, Advanced Malignant Solid Tumor, Hematopoietic and Lymphoid Cell Tumor Trial in Philadelphia (Capivasertib)

Active, not recruiting
Has Results
  • Advanced Lymphoma
  • +5 more
  • Philadelphia, Pennsylvania
    ECOG-ACRIN Cancer Research Group
Jun 28, 2022

Advanced Lymphoma, Advanced Malignant Solid Tumor, Hematopoietic and Lymphoid Cell Tumor Trial in Philadelphia (Trametinib

Active, not recruiting
  • Advanced Lymphoma
  • +5 more
  • Trametinib Dimethyl Sulfoxide
  • Philadelphia, Pennsylvania
    ECOG-ACRIN Cancer Research Group
Aug 13, 2022

Has a Pathologically Documented Unresectable Locally Advanced or Metastatic Solid Tumor or Lymphoma Trial in Shanghai (Phase I

Not yet recruiting
  • Has a Pathologically Documented Unresectable Locally Advanced or Metastatic Solid Tumor or Lymphoma
  • Phase I dose escalation
  • +3 more
  • Shanghai, Shanghai, China
    Fudan Cancer Hospital
Apr 24, 2023

Solid Tumor, Lymphoma Trial (LB1410)

Recruiting
  • Solid Tumor
  • Lymphoma
  • Shanghai, Shanghai, China
    Shanghai Pulmonary Hospital
Dec 27, 2022

Advanced Solid Tumors, Relapsed Or Refractory Non-Hodgkin Lymphoma Trial in Zhengzhou, Hangzhou (YH004)

Not yet recruiting
  • Advanced Solid Tumors
  • Relapsed Or Refractory Non-Hodgkin Lymphoma
  • Zhengzhou, Henan, China
  • +1 more
Oct 20, 2022

Chronic Lymphocytic Leukemia, Mantle Cell Lymphoma, Acute Lymphoblastic Leukemia Trial in Tampa (Fludarabine, Cyclophosphamide,

Recruiting
  • Chronic Lymphocytic Leukemia
  • +4 more
  • Tampa, Florida
    Moffitt Cancer Center
Jan 12, 2023

Cutaneous T Cell Lymphoma, Fungoides Mycosis Sezary Syndrome Trial in Ann Arbor (Pembrolizumab, Mogamulizumab)

Not yet recruiting
  • Cutaneous T Cell Lymphoma
  • Fungoides Mycosis Sezary Syndrome
  • Ann Arbor, Michigan
    University of Michigan Comprehensive Cancer Center
Jul 13, 2023

Advanced Solid Tumor, Advanced Lymphoma Trial in Australia, United States (CS5001)

Recruiting
  • Advanced Solid Tumor
  • Advanced Lymphoma
  • East Setauket, New York
  • +9 more
Jan 17, 2023

Non-Hodgkin Lymphoma, Multiple Myeloma Trial in China (Maplirpacept)

Not yet recruiting
  • Non-Hodgkin Lymphoma
  • Multiple Myeloma
  • Beijing, Beijing, China
  • +3 more
May 31, 2023

Solid Tumor, Non-Hodgkin Lymphoma Trial in Guangzhou, Shanghai (ADG106)

Active, not recruiting
  • Solid Tumor
  • Non-Hodgkin Lymphoma
  • Guangzhou, Guangdong, China
  • +1 more
Oct 15, 2022